Skip to main content

Table 3 Univariable and multivariable analysis for progression-free survival (PFS)

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Variables Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Treatment regimen
 mFOLFIRINOX vs Gemox 0.559 (0.307–1.020) 0.040 0.353 (0.180–0.694) 0.003
Age
 >58 vs ≤58 1.060 (0.579–1.939) 0.851   
Sex
 male vs female 0.844 (0.626–1.139) 0.268   
ECOG
 1 vs 0 1.220 (0.664–2.242) 0.523   
Primary tumor sites
 Intrahepatic Ref   Ref  
 Hilar 1.599 (0.869–2.944) 0.131 2.149 (1.113–4.151) 0.023
 Distal 0.512 (0.120–2.191) 0.367 0.493 (0.111–2.185) 0.352
Disease status
 Metastasis vs Locally advanced 1.111 (0.790–1.564) 0.545   
Liver metastasis 1.658 (0.891–3.088) 0.111 3.096 (1.535–6.246) 0.002
CA19–9
 >40 vs ≤40 1.867 (0.863–4.036) 0.113 3.622 (1.540–8.523) 0.003
  1. Bold values are statistically significant (p ≤ 0.05)
  2. Ref reference, HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group